VRD Regimen in Multiple Myeloma
VRD (bortezomib, lenalidomide, dexamethasone) is the preferred first-line treatment for transplant-eligible patients with newly diagnosed multiple myeloma, demonstrating superior progression-free and overall survival compared to doublet regimens, with a 4-year overall survival rate exceeding 80%. 1
Standard Dosing Schedule
The standard VRD regimen consists of: 2
- Bortezomib 1.3 mg/m² subcutaneously on days 1,8, and 15
- Lenalidomide 25 mg orally on days 1-14
- Dexamethasone 20 mg on the day of and day after bortezomib administration
- Cycle repeats every 3 weeks
Clinical Evidence and Outcomes
The SWOG S0777 randomized trial established VRD superiority, showing median progression-free survival of 43 months versus 30 months with lenalidomide-dexamethasone alone, and median overall survival of 75 months versus 64 months. 2 The most recent CEPHEUS trial (2025) further demonstrated that adding daratumumab to VRD (D-VRd) achieved 60.9% MRD-negativity versus 39.4% with VRD alone, with 43% lower risk of progression or death. 3
Treatment Duration by Patient Population
Transplant-Eligible Patients
- Administer 3-4 cycles of VRD induction before stem cell collection 4, 2
- Proceed to autologous stem cell transplantation (ASCT) with melphalan 200 mg/m² conditioning 4
- Follow with maintenance therapy 1
Transplant-Ineligible Patients
- Administer 8-12 cycles of VRD for standard-risk disease 1
- Continue with lenalidomide maintenance until progression 1
- For high-risk patients, consider bortezomib-based maintenance 1
Risk-Stratified Approach
Standard-risk patients treated with VRD achieve median PFS of 76.5 months and 10-year OS of 58%, while high-risk patients (del 17p, t(14;16), t(14;20)) have median PFS of 40.3 months and 10-year OS of 29%. 2 For high-risk patients, especially those with double-hit or triple-hit cytogenetics, adding daratumumab to VRD (Dara-VRd) is recommended, as it produces deeper responses in randomized phase II trials. 1
Special Clinical Situations
Renal Impairment
For acute renal failure due to light-chain cast nephropathy, bortezomib/cyclophosphamide/dexamethasone (VCd) is preferred initially, with consideration to switch to VRD after renal function improves. 2 Bortezomib requires no dose adjustment in renal failure, but lenalidomide requires dose reduction based on creatinine clearance. 1
Pre-existing Neuropathy
Daratumumab-lenalidomide-dexamethasone (DRd) is the preferred alternative for patients with baseline neuropathy who cannot tolerate bortezomib. 1 A 2024 real-world study showed DRd had 65% lower risk of progression/death compared to VRD in transplant-ineligible patients. 5
Adverse Event Management
Administer bortezomib subcutaneously rather than intravenously to reduce peripheral neuropathy risk. 2 If grade ≥2 neuropathy develops, reduce bortezomib dose or modify schedule. 2 Modified VRD-lite regimens (bortezomib on days 1,8,15,22 with reduced lenalidomide 15 mg on non-bortezomib days over 28-day cycles) demonstrate similar efficacy with significantly lower rates of grade ≥2 neuropathy (0% vs 27.2%) and grade ≥3 thrombocytopenia (0% vs 27.2%) compared to twice-weekly dosing. 6
Required Supportive Care
All patients on VRD require: 1
- Thromboprophylaxis: Aspirin for standard-risk patients; low-molecular weight heparin, warfarin, or direct thrombin inhibitors for high-risk patients
- Herpes zoster prophylaxis for all patients receiving bortezomib
- Pneumocystis jiroveci prophylaxis for all patients on dexamethasone
- Levofloxacin daily for the first two cycles in all newly diagnosed patients
Comparison with Alternative Regimens
VRD is preferred over carfilzomib-lenalidomide-dexamethasone (KRd) as initial therapy, as the ECOG ENDURANCE trial showed no significant benefit with KRd in standard-risk patients, while KRd carries higher risk of cardiac, renal, and pulmonary toxicity. 1 VRD is also preferred over daratumumab-based triplets for most patients based on cost and strength of long-term data, though DRd remains an important alternative. 1
Common Pitfalls to Avoid
- Do not administer bortezomib intravenously when subcutaneous administration reduces neuropathy 2
- Do not use prolonged induction (>4-6 cycles) in transplant-eligible patients as this may impair stem cell mobilization; plerixafor may be needed after prolonged lenalidomide exposure 1
- Do not forget dose adjustment of lenalidomide in renal impairment 1
- Do not omit thromboprophylaxis in patients receiving lenalidomide, as this significantly increases VTE risk 1